Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by...

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Lung cancer, particularly adenocarcinoma (ADC), is a leading cause of cancer mortality.
• Epidermal growth factor receptor (EGFR) mutations are common in lethal ADCs.
• Genetically engineered mouse models are crucial for understanding lung cancer development and drug responses.

Purpose of the Study:

• To analyze tumor heterogeneity evolution in EGFR-mutant lung cancer.
• To investigate the dynamic interactions within the tumor microenvironment (TME).
• To evaluate the effect of Unesbulin on tumor cells and their TME interactions.

Main Methods:

• High-resolution transcriptomics to study tumor heterogeneity and TME.
• Utilizing genetically engineered murine models of lung cancer.
• Magnetic resonance imaging (MRI) to assess tumor growth reduction.

Main Results:

• Identified vulnerable tumor-specific epithelial cells and their cross-talk with TME components (endothelial cells, fibroblasts, immune cells).
• Discovered that Unesbulin treatment abolishes the symbiotic interface shaping tumor aggressiveness.
• Unesbulin reduces B cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) activity.
• MRI confirmed decreased tumor growth following Unesbulin treatment.

Conclusions:

• Unesbulin effectively targets both cancer cells and their TME interactions in EGFR-mutant ADCs.
• Disruption of the tumor-TME interface by Unesbulin reduces tumor aggressiveness.
• Unesbulin shows promise as a novel therapeutic strategy for EGFR-mutant lung adenocarcinomas.